(Reuters) -Infant hospitalizations due to respiratory syncytial virus (RSV) infections in the United States dropped as much ...

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.

Of the RSV patients aged 60 or older, 23.0% were admitted to an ICU, 31.5% had acute organ failure, and 9.8% received IMV or ...

Far fewer babies had severe cases of the respiratory illness RSV, in a winter in which a new monoclonal and vaccine became ...

The infant mortality national rate dropped to about 5.5 infant deaths per 1,000 live births in 2024, according to provisional ...

Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related ...

ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

New multi-center US study finds RSV co-infection in children under two is not linked to worse clinical outcomes, challenging ...

Respiratory syncytial virus is the biggest cause of infant hospitalization, but a new vaccine and antiviral drug are likely ...

Vermont has the second lowest state fatality rate in the US (147.2 per 100K; Hawaii 112.9/100K). Mississippi (464.7/100K) and ...

By Dennis Thompson HealthDay ReporterTUESDAY, May 6, 2025 (HealthDay News) -- Newborns can be effectively protected against ...